Summit Therapeutics (SMMT) has had the highest return this decade by a large-cap US stock in the Biotechnology Industry, returning 1,333.1%.
| ASSET | DECADE | % RETURN |
|---|---|---|
Summit Therapeutics (SMMT) | 2020s | 1,333.13% |
Insmed (INSM) | 2020s | 586.52% |
Natera (NTRA) | 2020s | 414.38% |
argenx NV ADR (ARGX) | 2020s | 398.79% |
United Therapeutics (UTHR) | 2020s | 398.09% |
Alnylam Pharmaceuticals (ALNY) | 2020s | 302.31% |
AbbVie (ABBV) | 2020s | 229.22% |
BioNTech SE (BNTX) | 2020s | 186.15% |
Gilead Sciences (GILD) | 2020s | 125.95% |
Exelixis (EXEL) | 2020s | 117.05% |
BeiGene (ONC) | 2020s | 94.66% |
Vertex Pharmaceuticals (VRTX) | 2020s | 84.97% |
BridgeBio Pharma (BBIO) | 2020s | 59.11% |
Roivant Sciences (ROIV) | 2020s | 54.38% |
Ascendis Pharma A-S (ASND) | 2020s | 48.31% |
Regeneron Pharmaceuticals (REGN) | 2020s | 48.18% |
Genmab A-S (GMAB) | 2020s | 45.31% |
Amgen (AMGN) | 2020s | 43.73% |
Moderna (MRNA) | 2020s | 36.64% |
Neurocrine Biosciences (NBIX) | 2020s | 27.18% |
Haleon (HLN) | 2020s | 22.24% |
Ionis Pharmaceuticals (IONS) | 2020s | 15.93% |
Incyte (INCY) | 2020s | -2.51% |
EXACT Sciences (EXAS) | 2020s | -36.49% |
Biomarin Pharmaceutical (BMRN) | 2020s | -38.29% |
Large-cap stocks are treated as having a market cap of $10B+.
